Thrombolysis with Low-Dose Tissue Plasminogen Activator 3–4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan
暂无分享,去创建一个
Toru Yamashita | Koji Abe | Yasuyuki Ohta | Yasuhiro Manabe | K. Abe | K. Kashihara | Kentaro Deguchi | Hideki Kiriyama | K. Deguchi | S. Kono | T. Yamashita | Kenichi Kashihara | Y. Manabe | Y. Ohta | Kota Sato | Syoichiro Kono | Nozomi Hishikawa | N. Hishikawa | Kota Sato | R. Morihara | Y. Takao | Ryuta Morihara | Yoshiki Takao | Satoshi Inoue | S. Inoue | Hideki Kiriyama
[1] Keith Muir,et al. Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study , 2008, The Lancet.
[2] Toru Yamashita,et al. Dissociation and Protection of the Neurovascular Unit after Thrombolysis and Reperfusion in Ischemic Rat Brain , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] K. Abe,et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. , 2010, Current neurovascular research.
[4] M. Krause,et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. , 2015, The New England journal of medicine.
[5] Eric E. Smith,et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. , 2015, The New England journal of medicine.
[6] Ming Liu,et al. Edaravone for acute ischaemic stroke. , 2011, The Cochrane database of systematic reviews.
[7] Eric E. Smith,et al. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome: Data From Get With The Guidelines-Stroke , 2014, Stroke.
[8] K. Kimura,et al. Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients — A preliminary study , 2012, Journal of the Neurological Sciences.
[9] A. O'Connor. The Cochrane Database of Systematic Reviews , 2004 .
[10] I. Morita,et al. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. , 1988, Prostaglandins, leukotrienes, and essential fatty acids.
[11] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[12] Y. Shinohara,et al. Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) , 2006, Stroke.
[13] H. Lutsep,et al. Mechanical Thrombectomy for Acute Ischemic Stroke: Final Results of the Multi MERCI Trial , 2008, Stroke.
[14] K. Abe,et al. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. , 1988, Stroke.
[15] Jeffrey L Saver,et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.
[16] N. Omori,et al. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[17] Gary A. Ford,et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.
[18] K. Abe,et al. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[19] K. Goto,et al. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. , 2009, Internal medicine.
[20] R. Verma,et al. A randomized controlled clinical trial to compare the safety and efficacy of edaravone in acute ischemic stroke , 2011, Annals of Indian Academy of Neurology.
[21] Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease , 2009, Stroke.
[22] Takeshi Hayashi,et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain , 2004, Neurological research.
[23] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[24] Hester F. Lingsma,et al. A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.
[25] K. Abe,et al. In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice , 2011, Brain Research.
[26] 大友英一. Clinical efficacy of a free radical scavenger, MCI-186 on acute cerebral infarction-early phase 2 clinical trial , 1998 .
[27] A. Hishida. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance , 2007, Clinical and Experimental Nephrology.
[28] Eric E. Smith,et al. Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Guidelines, Update 2014 , 2015, International journal of stroke : official journal of the International Stroke Society.
[29] R Frayne,et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[30] M. Harada,et al. Evaluation of initial diffusion-weighted image findings in acute stroke patients using a semiquantitative score. , 2009, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.
[31] E. Mori,et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[32] Mark Parsons,et al. Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR , 2010, The Lancet Neurology.
[33] Werner Hacke,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.
[34] Tammy Hoffmann,et al. Clinical Guidelines for Stroke Management 2010 , 2010 .